Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: The objective of this study was to identify biomarkers associated with immunogenic cell death (ICD) in lung squamous cell carcinoma (LUSC), focusing on subtypes with distinct immunological characteristics and prognosis. Given the heterogeneous nature of LUSC, understanding ICD's role is crucial for developing tailored therapeutic strategies.
Patients And Methods: RNA sequencing data from 504 LUSC samples were analyzed using unsupervised clustering to identify ICD-related gene expression patterns. These patterns were linked to immune scores, immune cell infiltration, and clinical outcomes. A separate dataset was used to validate the association between ICD-related subtypes and immunotherapy efficacy.
Results: Unsupervised clustering revealed two distinct ICD-related subtypes with significantly different immune scores, immune cell infiltration levels, and prognosis. A prognostic model was developed based on differentially expressed ICD-related genes, which demonstrated strong predictive power for patient survival and immune response. This model may offer valuable insights for clinical decision-making, particularly for immunotherapy strategies.
Conclusion: This study identified key ICD-related biomarkers and developed a prognostic model that can enhance our understanding of ICD in LUSC, ultimately guiding personalized treatment approaches.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998936 | PMC |
| http://dx.doi.org/10.2147/OTT.S503419 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[A case of lung poorly differentiated squamous cell carcinoma-associated retinopathy].
Zhonghua Yan Ke Za Zhi
September 2025
Department of Respiratory, The First People's Hospital of Xianyang, Xianyang 712000, China.
A 65-year-old male patient presented with "blurred vision in the right eye for 1 week". At the first visit, the best corrected visual acuity (BCVA) of both eyes was 0.8, no obvious abnormalities were observed in fundus examination, and optical coherence tomography (OCT) revealed the loss of outer retinal layers adjacent to the macula in the right eye.
View Article and Find Full Text PDFThe International Association for the Study of Lung Cancer Staging Project: The Impact of Smoking Status on Lung Cancer Staging in the Ninth Edition of the TNM Classification.
J Thorac Oncol
August 2025
Department of Radiation Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky.
Introduction: Cigarette smoking negatively affects lung cancer prognosis. Incorporating smoking history into stage-stratified survival analyses may improve prognostication.
Methods: Using the International Association for the Study of Lung Cancer ninth edition NSCLC database, we evaluated the association between smoking status at diagnosis and overall survival (OS) using Kaplan-Meier plots and multivariate Cox proportional hazard regression models adjusted for age, region, sex, histologic type, performance status, and TNM stage.
TMBquant: an explainable AI-powered caller advancing tumor mutation burden quantification across heterogeneous samples.
Brief Bioinform
August 2025
Department of Respiratory Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157, Xiwu Road, Xincheng District, Xi'an 710004, China.
Accurate tumor mutation burden (TMB) quantification is critical for immunotherapy stratification, yet remains challenging due to variability across sequencing platforms, tumor heterogeneity, and variant calling pipelines. Here, we introduce TMBquant, an explainable AI-powered caller designed to optimize TMB estimation through dynamic feature selection, ensemble learning, and automated strategy adaptation. Built upon the H2O AutoML framework, TMBquant integrates variant features, minimizes classification errors, and enhances both accuracy and stability across diverse datasets.
View Article and Find Full Text PDFFirst-Line Aumolertinib in -Mutant Advanced Non-Small Cell Lung Cancer: A Multicenter Real-World Retrospective Study with a Four-Year Follow-Up.
Oncol Res
September 2025
Department of Oncology, Affiliated Hospital of Guilin Medical University, Guilin, 541001, China.
Background: The use of third-generation different tyrosine kinase inhibitors (TKIs) is considered the most effective option for treating advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) mutations. However, there is limited information on the efficacy and safety of aumolertinib in patients remains these cases.
Methods: The clinical records of patients receiving aumolertinib as first-line therapy across four hospitals in the Guangxi Zhuang Autonomous Region from April 2020 to December 2021 were retrospectively analyzed, using progression-free survival (PFS) as the primary endpoint and overall survival (OS) representing the secondary endpoint.
Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses.
ESMO Open
September 2025
Academic Medical Oncology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties, University of Genova, Genova, Italy.
Background: Immunotherapy has rapidly changed the treatment of early-stage non-small-cell lung cancer (NSCLC) in recent years. We aimed to summarize available evidence on the use of immunotherapy in neoadjuvant/perioperative and adjuvant settings for resectable NSCLC and explore some controversial subgroups.
Materials And Methods: Systematic literature research was carried out for randomized controlled trials of neoadjuvant/perioperative chemo-immunotherapy or adjuvant immunotherapy for resectable NSCLC.